The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema. The average weight loss among those taking the new drug was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback